Content about HAYWARD

September 13, 2013

On Friday, UrgentRx, developer of fast-acting, over-the-counter flavored powder medications, announced Rick Hayward will be joining the company as the sales director for the food, drug and mass channels.

DENVER — On Friday, UrgentRx, developer of fast-acting, over-the-counter flavored powder medications, announced Rick Hayward will be joining the company as the sales director for the food, drug and mass channels.

November 1, 2011

Drug maker Impax Labs reported sales of $119.8 million and profits of $20 million in third quarter 2011, according to an earnings report released Tuesday.

HAYWARD, Calif. — Drug maker Impax Labs reported sales of $119.8 million and profits of $20 million in third quarter 2011, according to an earnings report released Tuesday.

The latest sales figures represented a $12.2 million increase over third quarter 2010, while profits were $4.2 million higher.

December 16, 2010

GlaxoSmithKline will pay Impax Pharmaceuticals $11.5 million upfront to exclusively sell Impax's investigational Parkinson’s disease treatment.

LONDON and HAYWARD, Calif. — GlaxoSmithKline will pay Impax Pharmaceuticals $11.5 million upfront to exclusively sell Impax's investigational Parkinson’s disease treatment.

In addition to the $11.5 million upfront payment, Impax Pharmaceuticals, the branded drug division of Impax Labs, is eligible to receive potential payments of up to $175 million upon the successful achievement of development and commercialization milestones.